|
|
| VGX
Pharmaceuticals announced the appointment of Thomas S. Kim, J.D.
as Senior Director, Intellectual Property
|
| Blue
Bell, PA – March 12, 2007 – |
|
VGX Pharmaceuticals announced the appointment of Thomas
S. Kim, J.D. as Senior Director, Intellectual Property.
Mr. Kim is an experienced patent attorney, working for both large Intellectual
Property law firms and Fortune 500 companies. Most recently, Mr. Kim served
as Senior Counsel to the gene discovery group at DuPont Company, where
he provided legal counsel on a variety of patent issues and drafted and
prosecuted patent applications related to DNA molecules and transgenic
organisms. In private practice, most recently with the national firm of
Woodcock Washburn, LLP, Mr. Kim has counseled clients ranging from start-up
to Fortune 50 companies on various chemical, pharmaceutical and biotech
patent matters.
Mr. Kim received a J.D. from Washington University School of Law in St.
Louis, a M.S. in Biochemistry from the University of Illinois, and a B.S.
in Chemistry from the Georgia Institute of Technology. Mr. Kim is licensed
to practice law in the Commonwealth of Pennsylvania, State of Illinois,
and is registered to practice before the U.S. Patent and Trademark Office.
“Addition of Thomas to our management team highlights the significant
expansion of our intellectual property portfolio — arguably our
most valuable asset. Thomas is highly qualified to manage our overall
efforts to maximize the value of this leading edge technology,”
said Dr. J. Joseph Kim, CEO and President.
VGX Pharmaceuticals has over 70 families of US patents and patent application
as well as over 400 patent filings worldwide. “Exploiting and commercializing
our strong IP position is a key component in our global strategy of becoming
a leading global Biopharmaceutical Company,” added Dr. Kim.
Cautionary
Factors That May Affect Future Results - Materials in this
Web site contain information that includes or is based upon forward-looking
statements within the meaning of the Securities Litigation Reform
Act of 1995. Forward-looking statements relate to expectations or
forecasts of future events. You can identify these statements by the
fact that they do not relate strictly to historical or current facts.
They use words such as "anticipate," "estimate,"
"expect," "project," "intend," "plan,"
"believe," and other words and terms of similar meaning
in connection with a discussion of potential future events, circumstances
or future operating or financial performance. In particular, these
include statements relating to future actions, prospective products
or product approvals, future performance or results of current and
anticipated products, sales efforts, expenses, the outcome of contingencies
such as legal proceedings, and financial results. Any or all of our
forward-looking statements here or in other publications may turn
out to be wrong. They can be affected by inaccurate assumptions or
by known or unknown risks and uncertainties. Many such factors will
be important in determining our actual future results. Consequently,
no forward-looking statement can be guaranteed, and forward-looking
statements may be adversely affected by factors, including general
market conditions, competitive product development, product availability,
current and future branded and generic competition, federal and state
regulations and legislation, manufacturing issues, timing of the elimination
of trade buying, patent positions, litigations and investigations.
Our actual results may vary materially, and there are no guarantees
about the performance or valuation of VGX stock. It is also important
to read the disclosure notice contained in many of the individual
VGX documents available on this Web site as many contain important
information on such cautionary factors as of the date of the individual
document. We undertake no obligation to correct or update any forward-looking
statements, whether as a result of new information, future events
or otherwise. You are advised, however, to consult any further disclosures
we make on related subjects in our reports. |
About VGX
Pharmaceuticals
VGX Pharmaceuticals is a biopharmaceutical company with small molecules
and biologics product candidates for the treatment of infectious diseases,
cancer and inflammatory diseases. The Company’s clinical development
programs include PICTOVIR™ for HIV infection and VGX-410C for chronic
HCV infection, both of which are currently in Phase II clinical trials.
In addition, Phase I clinical trials will be initiated in 2007 for VGX-150
for the treatment of Melanoma and VGX-1027 for inflammatory diseases. VGX’s
research pipelines include new generation of DNA vaccines and therapeutics
as well as CELLECTRA™, a proprietary DNA delivery device. The product
candidates and technology programs are protected by the Company’s
extensive global intellectual property portfolio. More information about
VGX can be found at www.vgxp.com.
Company Contact:
Kevin W. Rassas
Senior Vice President
Tel. 267.440.4208
Fax 267.440.4242
E-mail: Rassas@vgxp.com
www.vgxp.com
|
